Wellenstein, Max D.
Coffelt, Seth B.
Duits, Danique E. M.
van Miltenburg, Martine H.
Slagter, Maarten
de Rink, Iris
Henneman, Linda
Kas, Sjors M.
Prekovic, Stefan
Hau, Cheei-Sing
Vrijland, Kim
Drenth, Anne Paulien
de Korte-Grimmerink, Renske
Schut, Eva
van der Heijden, Ingrid
Zwart, Wilbert
Wessels, Lodewyk F. A.
Schumacher, Ton N.
Jonkers, Jos
de Visser, Karin E.
Article History
Received: 15 February 2018
Accepted: 26 June 2019
First Online: 31 July 2019
Competing interests
: M.D.W., S.B.C., D.E.M.D., M.H.v.M., M.S., I.d.R., L.H., S.M.K., S.P., C.-S.H., K.V., A.P.D., R.d.K.-G., E.S., I.v.d.H., W.Z. and J.J. report no competing interests. L.F.A.W. reports research funding from Genmab. T.N.S. is a consultant for Adaptive Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Amgen, Merus, Neon Therapeutics, Scenic Biotech and Third Rock Ventures, reports research support from Merck, Bristol-Myers Squibb, Merck KGaA, and is stockholder in AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, Neon Therapeutics and Scenic Biotech, all outside the scope of this work. K.E.d.V. reports research funding from Roche and is consultant for Third Rock Ventures, outside the scope of this work.